Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Mukherjee, Jean ^a   Dmitriev, Igor ^b   Debatis, Michelle ^a   Tremblay, Jacqueline M ^a   Beamer, Gillian ^a   Kashentseva, Elena A ^b   Curiel, David T ^b   Shoemaker, Charles B ^a  

^a TUFTS UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALBUMIN; ALBUMIN BINDING PEPTIDE; BINDING PROTEIN; BOTULINUM ANTISERUM; BOTULINUM TOXIN A; HEAVY CHAIN ONLY VH DOMAIN BASED NEUTRALIZING AGENT; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BOTULISM; CONTROLLED STUDY; FEMALE; IMMUNE COMPLEX DEPOSITION; IMMUNOGENICITY; LD 50; MOUSE; NONHUMAN; PLASMA HALF LIFE; VIRAL GENE DELIVERY SYSTEM; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; BOTULINUM ANTITOXIN; BOTULISM; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; MICE; VACCINATION;

EID: 84919484445     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106422     Document Type: Article

References (50)

1. Patel K, Cai S, Singh BR (2014) Current strategies for designing antidotes against botulinum neurotoxins. Expert Opin Drug Discov 9: 319-333.
2. Rainey GJ, Young JA (2004) Antitoxins: novel strategies to target agents of bioterrorism. Nature reviews Microbiology 2: 721-726. (Pubitemid 39200063)
3. Casadevall A (2002) Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 8: 833-841.
4. Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, et al. (2012) Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem 430: 141-150.
5. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, et al. (2012) A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS ONE 7: e29941.
6. Tremblay JM, Mukherjee J, Leysath CE, Debatis M, Ofori K, et al. (2013) A single VHH-based toxin neutralizing agent and an effector antibody protects mice against challenge with Shiga toxins 1 and 2. Infect Immun.
7. Vance DJ, Tremblay JM, Mantis NJ, Shoemaker CB (2013) Stepwise Engineering of Heterodimeric Single Domain Camelid VHH Antibodies that Passively Protect Mice from Ricin Toxin. J Biol Chem.
8. Sepulveda J, Mukherjee J, Tzipori S, Simpson LL, Shoemaker CB (2010) Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun 78: 756-763.
9. Sofer-Podesta C, Ang J, Hackett NR, Senina S, Perlin D, et al. (2009) Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun 77: 1561-1568.
10. De BP, Hackett NR, Crystal RG, Boyer JL (2008) Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. Mol Ther 16: 203-209.
11. Kasuya K, Boyer JL, Tan Y, Alipui DO, Hackett NR, et al. (2005) Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an antiprotective antigen single-chain antibody. Mol Ther 11: 237-244.
12. Noel D, Pelegrin M, Kramer S, Jacquet C, Skander N, et al. (2002) High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther 13: 1483-1493.
13. Skaricic D, Traube C, De B, Joh J, Boyer J, et al. (2008) Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology 378: 79-85.
14. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, et al. (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584-590. (Pubitemid 41724897)
15. Fang J, Yi S, Simmons A, Tu GH, Nguyen M, et al. (2007) An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 15: 1153-1159. (Pubitemid 46813618)
16. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR (2002) Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 76: 8769-8775. (Pubitemid 34864072)
17. Zuber C, Mitteregger G, Schuhmann N, Rey C, Knackmuss S, et al. (2008) Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J Gen Virol 89: 2055-2061.
18. Tutykhina IL, Sedova ES, Gribova IY, Ivanova TI, Vasilev LA, et al. (2013) Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res 97: 318-328.
19. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D (2002) Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13: 603-608. (Pubitemid 35448063)
20. Nguyen A, Reyes AE 2nd, Zhang M, McDonald P, Wong WL, et al. (2006) The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein engineering, design & selection : PEDS 19: 291-297. (Pubitemid 43999639)
21. Liang M, Guttieri M, Lundkvist A, Schmaljohn C (1997) Baculovirus expression of a human G2-specific, neutralizing IgG monoclonal antibody to Puumala virus. Virology 235: 252-260. (Pubitemid 27394338)
22. Morimoto K, Schnell MJ, Pulmanausahakul R, McGettigan JP, Foley HD, et al. (2001) High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods 252: 199-206. (Pubitemid 32382104)
23. Jiang M, Shi W, Zhang Q, Wang X, Guo M, et al. (2006) Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 12: 6179-6185. (Pubitemid 44703784)
24. Kasala D, Choi JW, Kim SW, Yun CO (2014) Utilizing adenovirus vectors for gene delivery in cancer. Expert Opin Drug Deliv 11: 379-392.
25. Beatty MS, Curiel DT (2012) Chapter two-Adenovirus strategies for tissue-specific targeting. Adv Cancer Res 115: 39-67.
26. Verheesen P, Roussis A, de Haard HJ, Groot AJ, Stam JC, et al. (2006) Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation. Biochim Biophys Acta 1764: 1307-1319. (Pubitemid 44403970)
27. Monegal A, Ami D, Martinelli C, Huang H, Aliprandi M, et al. (2009) Immunological applications of single-domain llama recombinant antibodies isolated from a naive library. Protein Eng Des Sel 22: 273-280.
28. Koide A, Koide S (2012) Affinity maturation of single-domain antibodies by yeast surface display. Methods Mol Biol 911: 431-443.
29. Muyldermans S (2013) Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82: 775-797.
30. Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S (2013) Nanobodies and their potential applications. Nanomedicine (Lond) 8: 1013-1026.
31. Lopez-Requena A, Burrone OR, Cesco-Gaspere M (2012) Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol 2: 159.
32. Losman MJ, Qu Z, Krishnan IS, Wang J, Hansen HJ, et al. (1999) Generation and monitoring of cell lines producing humanized antibodies. Clin Cancer Res 5: 3101s-3105s. (Pubitemid 29493902)
33. Annoni A, Brown BD, Cantore A, Sergi LS, Naldini L, et al. (2009) In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 114: 5152-5161.
34. Matrai J, Cantore A, Bartholomae CC, Annoni A, Wang W, et al. (2011) Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 53: 1696-1707.
35. Haisma HJ, Bellu AR (2011) Pharmacological interventions for improving adenovirus usage in gene therapy. Mol Pharm 8: 50-55.
36. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, et al. (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807. (Pubitemid 27446464)
37. Shayakhmetov DM, Li ZY, Ni S, Lieber A (2004) Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 78: 5368-5381. (Pubitemid 38581487)
38. Smith JS, Xu Z, Byrnes AP (2008) A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells. J Virol Methods 147: 54-60. (Pubitemid 350250848)
39. Tao N, Gao GP, Parr M, Johnston J, Baradet T, et al. (2001) Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3: 28-35. (Pubitemid 32509802)
40. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, et al. (1997) Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 71: 624-629. (Pubitemid 26412334)
41. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG (1997) Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8: 37-44. (Pubitemid 27075341)
42. Danthinne X, Imperiale MJ (2000) Production of first generation adenovirus vectors: a review. Gene Ther 7: 1707-1714.
43. Parks RJ (2000) Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clin Genet 58: 1-11.
44. Wang II, Huang II (2000) Adenovirus technology for gene manipulation and functional studies. Drug Discov Today 5: 10-16.
45. Kontermann RE (2011) Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 22: 868-876.
46. Luo J, Deng ZL, Luo X, Tang N, Song WX, et al. (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247. (Pubitemid 46908240)
47. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95: 2509-2514. (Pubitemid 28145972)
48. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
49. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, et al. (1996) Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7: 215-222. (Pubitemid 26044840)
50. Maizel JV, Jr., White DO, Scharff MD (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36: 115-125.